Sydney C W Tang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5679866/publications.pdf

Version: 2024-02-01

227 papers 9,248 citations

51 h-index 84 g-index

230 all docs

230 docs citations

times ranked

230

9840 citing authors

#	Article	IF	Citations
1	De novo and relapsing glomerulonephritis after <scp>COVID</scp> â€19 vaccination: how much do we know?. Nephrology, 2022, 27, 5-6.	1.6	11
2	Could SGLT2 inhibitors be the next "game changer―in focal segmental glomerulosclerosis?. Nephrology Dialysis Transplantation, 2022, , .	0.7	O
3	Personalized immunosuppression after kidney transplantation. Nephrology, 2022, , .	1.6	9
4	IgA Nephropathy: A Tale of 3 Continents. Glomerular Diseases, 2022, 2, 1-3.	1.0	0
5	Singleâ€cell RNA Sequencing Identified Novel Nr4a1 ⁺ Ear2 ⁺ Antiâ€Inflammatory Macrophage Phenotype under Myeloidâ€TLR4 Dependent Regulation in Antiâ€Glomerular Basement Membrane (GBM) Crescentic Glomerulonephritis (cGN). Advanced Science, 2022, 9, e2200668.	11.2	10
6	What can a thrombus in the <code><scp>superior</scp></code> vena cava (SVC) <code></code> do to a jugular haemodialysis catheter?. Nephrology, 2022, , .	1.6	0
7	Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLoS Medicine, 2022, 19, e1004018.	8.4	22
8	Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors. Kidney Research and Clinical Practice, 2022, 41, 682-698.	2.2	4
9	Direct Renin Inhibition in Non-diabetic chronic Kidney disease (DRINK): a prospective randomized trial. Nephrology Dialysis Transplantation, 2021, 36, 1648-1656.	0.7	7
10	Vaccination in patients with chronic kidney diseaseâ€"Review of current recommendations and recent advances. Nephrology, 2021, 26, 5-11.	1.6	24
11	Aetiology, practice patterns and burden of <scp>endâ€stage</scp> kidney disease in South Asia and <scp>Southâ€East</scp> Asia: A questionnaireâ€based survey. Nephrology, 2021, 26, 142-152.	1.6	7
12	Protective role of kallistatin in renal fibrosis via modulation of Wnt/ \hat{l}^2 -catenin signaling. Clinical Science, 2021, 135, 429-446.	4.3	12
13	Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology, 2021, 26, 491-500.	1.6	63
14	Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy. Frontiers in Physiology, 2021, 12, 650888.	2.8	9
15	Clinicopathological features of Chinese patients with Bâ€cell lymphoproliferative disorders and kidney infiltration. Nephrology, 2021, 26, 650-658.	1.6	1
16	Conversion from Aranesp® to NESP ® in dialysis patients—Exploration of dosing strategies and the feasibility of extending the dosing interval. Nephrology, 2021, 26, 733-741.	1.6	0
17	Impact of National Economy and Policies on End-Stage Kidney Care in South Asia and Southeast Asia. International Journal of Nephrology, 2021, 2021, 1-11.	1.3	5
18	SYmptom-Based STratification of DiabEtes Mellitus by Renal Function Decline (SYSTEM): A Retrospective Cohort Study and Modeling Assessment. Frontiers in Medicine, 2021, 8, 682090.	2.6	5

#	Article	IF	CITATIONS
19	Single-Cell RNA Sequencing Reveals the Immunological Profiles of Renal Allograft Rejection in Mice. Frontiers in Immunology, 2021, 12, 693608.	4.8	13
20	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Post Hoc Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2731-2734.	6.1	6
21	Regulatory role and mechanisms of myeloid TLR4 in anti-GBM glomerulonephritis. Cellular and Molecular Life Sciences, 2021, 78, 6721-6734.	5.4	9
22	Current treatment of IgA nephropathy. Seminars in Immunopathology, 2021, 43, 717-728.	6.1	52
23	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
24	Efficacy, safety and response predictors of adjuvant astragalus for diabetic kidney disease (READY): study protocol of an add-on, assessor-blind, parallel, pragmatic randomised controlled trial. BMJ Open, 2021, 11, e042686.	1.9	8
25	Tubule-specific deletion of LincRNA-p21 ameliorates lipotoxic kidney injury. Molecular Therapy - Nucleic Acids, 2021, 26, 1280-1290.	5.1	3
26	Acetylâ€coenzyme A carboxylase beta gene polymorphism does not predict cardiovascular risk susceptibility in Chinese type 2 diabetic individuals. Nephrology, 2021, , .	1.6	1
27	Vascular age is associated with the risk of dialysis or death in chronic kidney disease. Nephrology, 2020, 25, 314-322.	1.6	7
28	Editorial: diabetic kidney disease: an update in recent clinical and basic research. Nephrology Dialysis Transplantation, 2020, 35, 725-728.	0.7	0
29	Effect of non-surgical periodontal therapy on renal function in chronic kidney disease patients with periodontitis: a systematic review and meta-analysis of interventional studies. Clinical Oral Investigations, 2020, 24, 1607-1618.	3.0	15
30	A global perspective on the crosstalk between saturated fatty acids and Toll-like receptor 4 in the etiology of inflammation and insulin resistance. Progress in Lipid Research, 2020, 77, 101020.	11.6	76
31	Dialysis Care and Dialysis Funding in Asia. American Journal of Kidney Diseases, 2020, 75, 772-781.	1.9	43
32	Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 399-403.	0.5	2
33	Peritoneal dialysis: the ideal bridge from conservative therapy to kidney transplant. Journal of Nephrology, 2020, 33, 1189-1194.	2.0	12
34	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	1.6	17
35	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE – EXECUTIVE SUMMARY. Nephrology, 2020, 25, 3-11.	1.6	9
36	Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease – An Executive Summary. Nephrology, 2020, 25, 809-817.	1.6	12

3

#	Article	IF	CITATIONS
37	Blocking Connexin-43 mediated hemichannel activity protects against early tubular injury in experimental chronic kidney disease. Cell Communication and Signaling, 2020, 18, 79.	6.5	28
38	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	5.2	126
39	COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease. The American Journal of Chinese Medicine, 2020, 48, 737-762.	3.8	273
40	Patients' and clinicians' expectations on integrative medicine Services for Diabetes: a focus group study. BMC Complementary Medicine and Therapies, 2020, 20, 205.	2.7	9
41	Dietary phytochemical approaches to stem cell regulation. Journal of Functional Foods, 2020, 66, 103822.	3.4	11
42	Innate immunity in diabetic kidney disease. Nature Reviews Nephrology, 2020, 16, 206-222.	9.6	273
43	Not even a peripheral role for statins in end-stage renal disease?. Nephrology Dialysis Transplantation, 2020, 35, 1645-1647.	0.7	2
44	The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis. Clinical Science, 2020, 134, 2873-2891.	4.3	20
45	A Longitudinal Study on the Prevalence and Risk Factors for Depression and Anxiety, Quality of Life, and Clinical Outcomes in Incident Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2019, 39, 74-82.	2.3	17
46	A systematic review and meta-analysis of randomized controlled trials of cognitive behavioral therapy for hemodialysis patients with depression. Journal of Psychosomatic Research, 2019, 126, 109834.	2.6	26
47	Amelioration of Endoplasmic Reticulum Stress by Mesenchymal Stem Cells via Hepatocyte Growth Factor/c-Met Signaling in Obesity-Associated Kidney Injury. Stem Cells Translational Medicine, 2019, 8, 898-910.	3.3	31
48	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	5.2	232
49	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	13.7	408
50	Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology. Nephrology, 2019, 24, 9-26.	1.6	4
51	Oncology in nephrology comes of age: A focus on chronic dialysis patients. Nephrology, 2019, 24, 380-386.	1.6	5
52	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
53	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
54	An update on cancer after kidney transplantation. Nephrology Dialysis Transplantation, 2019, 34, 914-920.	0.7	46

#	Article	IF	CITATIONS
55	Glomerular Filtration Rates in Asians. Advances in Chronic Kidney Disease, 2018, 25, 41-48.	1.4	37
56	Gout: A Disease of Kings. Contributions To Nephrology, 2018, 192, 77-81.	1.1	20
57	Nonâ€invasive assessment of kidney allograft fibrosis with shear wave elastography: A radiologicalâ€pathological correlation analysis. International Journal of Urology, 2018, 25, 450-455.	1.0	30
58	SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?. Kidney International, 2018, 93, 22-24.	5.2	9
59	Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 1323-1332.	0.7	62
60	Activated renal tubular Wnt/ \hat{l}^2 -catenin signalingÂtriggers renal inflammation duringÂoverload proteinuria. Kidney International, 2018, 93, 1367-1383.	5.2	47
61	Disease burden and challenges of chronic kidney disease in North and East Asia. Kidney International, 2018, 94, 22-25.	5.2	43
62	Nâ€acetylâ€serylâ€aspartylâ€lysylâ€proline mediates the antiâ€fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice. Nephrology, 2018, 23, 297-307.	1.6	7
63	Posttransplant Lymphoproliferative Disorders in Chinese Kidney Transplant Recipients. Transplantation, 2018, 102, S321.	1.0	0
64	Downregulation of Aquaporin 9 Exacerbates Beta-amyloid-induced Neurotoxicity in Alzheimer's Disease Models In vitro and In vivo. Neuroscience, 2018, 394, 72-82.	2.3	10
65	CKD prevention: Perspectives in Hong Kong. Nephrology, 2018, 23, 72-75.	1.6	3
66	Role of Mesangial-Podocytic-Tubular Cross-Talk in IgA Nephropathy. Seminars in Nephrology, 2018, 38, 485-495.	1.6	28
67	Treatment of IgA Nephropathy: Evolution Over Half a Century. Seminars in Nephrology, 2018, 38, 531-540.	1.6	17
68	An Overview of IgA Nephropathy: 50 Years On. Seminars in Nephrology, 2018, 38, 433-434.	1.6	6
69	Staged Screening of BK Virus-Associated Nephropathy using Urine Cytology and Serum Quantitative Polymerase Chain Reaction. Transplantation, 2018, 102, S227.	1.0	0
70	An evidenceâ€based systematic review of the offâ€label uses of lisinopril. British Journal of Clinical Pharmacology, 2018, 84, 2502-2521.	2.4	9
71	Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong. Journal of Viral Hepatitis, 2018, 25, 209-213.	2.0	27
72	Proteinuria reaffirmed as a risk modifier in diabetic chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 1873-1874.	0.7	4

#	Article	IF	CITATIONS
73	Ellagitannins from Pomegranate Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis in Rats while Enhancing Its Chemotoxicity against HT-29 Colorectal Cancer Cells through Intrinsic Apoptosis Induction. Journal of Agricultural and Food Chemistry, 2018, 66, 7054-7064.	5. 2	17
74	A Rare Case of Famotidine-Induced Delirium in a Peritoneal Dialysis Patient. Peritoneal Dialysis International, 2017, 37, 118-120.	2.3	5
75	<i>Mycobacterium chlorophenolicum</i> : An uncommon cause of peritonitis in a peritoneal dialysis patient. Nephrology, 2017, 22, 498-499.	1.6	3
76	Colossal renal allograft hydronephrosis causing abdominal distension. Nephrology, 2017, 22, 420-421.	1.6	0
77	Acute thyroiditis: An underâ€recognized complication of parathyroidectomy in endâ€stage renal failure patients with secondary hyperparathyroidism. Nephrology, 2017, 22, 572-572.	1.6	3
78	Ficus virens proanthocyanidins induced apoptosis in breast cancer cells concomitantly ameliorated 5-fluorouracil induced intestinal mucositis in rats. Food and Chemical Toxicology, 2017, 110, 49-61.	3.6	32
79	ESRD in South-East Asia. , 2017, , 149-156.		1
80	Cancer risk in patients with diabetic nephropathy. Medicine (United States), 2017, 96, e8077.	1.0	10
81	Relatives in silent kidney disease screening (<scp>RISKS</scp>) study: <scp>A C</scp> hinese cohort study. Nephrology, 2017, 22, 35-42.	1.6	25
82	Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complications. Health and Quality of Life Outcomes, 2017, 15, 125.	2.4	23
83	Risk factors and prognosis of late acute rejection in Chinese kidney transplant recipients. Nephrology, 2017, 22, 985-992.	1.6	0
84	Human induced pluripotent stem cell-derived mesenchymal stem cells prevent adriamycin nephropathy in mice. Oncotarget, 2017, 8, 103640-103656.	1.8	17
85	Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers. Oncotarget, 2017, 8, 44833-44841.	1.8	12
86	Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong. Oncotarget, 2017, 8, 96903-96912.	1.8	14
87	Recent advances in managing and understanding diabetic nephropathy. F1000Research, 2016, 5, 1044.	1.6	29
88	Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial. BMJ Open, 2016, 6, e010741.	1.9	7
89	Cancer Incidence and Mortality in Chronic Dialysis Population: A Multicenter Cohort Study. American Journal of Nephrology, 2016, 43, 153-159.	3.1	50
90	IgA nephropathy. Nature Reviews Disease Primers, 2016, 2, 16001.	30.5	322

#	Article	IF	Citations
91	Recent Progress in Stem Cell Therapy for Diabetic Nephropathy. Kidney Diseases (Basel, Switzerland), 2016, 2, 20-27.	2.5	27
92	Chinese medicines in the treatment of experimental diabetic nephropathy. Chinese Medicine, 2016, 11, 6.	4.0	7
93	Diabetic nephropathy: landmark clinical trials and tribulations. Nephrology Dialysis Transplantation, 2016, 31, 359-368.	0.7	80
94	Dendrobium officinale polysaccharides ameliorated pulmonary function while inhibiting mucin-5AC and stimulating aquaporin-5 expression. Journal of Functional Foods, 2016, 21, 359-371.	3.4	28
95	Proteinuria is associated with sleep apnea in chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 772-779.	0.7	9
96	Downregulation of renal tubular Wnt/ \hat{l}^2 -catenin signaling by Dickkopf-3 induces tubular cell death in proteinuric nephropathy. Cell Death and Disease, 2016, 7, e2155-e2155.	6.3	16
97	Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Current Medical Research and Opinion, 2016, 32, 1097-1108.	1.9	14
98	Kallistatin protects against diabetic nephropathy inÂdb/db mice by suppressing AGE-RAGE-induced oxidative stress. Kidney International, 2016, 89, 386-398.	5.2	75
99	In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney International, 2016, 89, 683-692.	5. 2	61
100	Recent advances in the understanding and management of IgA nephropathy. F1000Research, 2016, 5, 161.	1.6	4
101	Expression of aquaporinÂ5 in primary carcinoma and lymph node metastatic carcinoma of non-small cell lung cancer. Oncology Letters, 2015, 9, 2799-2804.	1.8	24
102	Progressive outer retinal necrosis in a renal transplant recipient: a rare treatment success. Transplant Infectious Disease, 2015, 17, 396-399.	1.7	1
103	Role of bone morphogenetic protein-7 in renal fibrosis. Frontiers in Physiology, 2015, 6, 114.	2.8	62
104	N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	10
105	Mediators of Inflammation: Inflammation in Cancer, Chronic Diseases, and Wound Healing. Mediators of Inflammation, 2015, 2015, 1-2.	3.0	21
106	Fibroblast Growth Factor 23 and Vascular Calcification: Is It Set in Stone?. American Journal of Nephrology, 2015, 42, 389-390.	3.1	0
107	Screening Algorithm for BK Virus-Associated Nephropathy Using Sequential Testing of Urinary Cytology: A Probabilistic Model Analysis. American Journal of Nephrology, 2015, 42, 410-417.	3.1	8
108	Edible plants from traditional Chinese medicine is a promising alternative for the management of diabetic nephropathy. Journal of Functional Foods, 2015, 14, 12-22.	3.4	18

#	Article	IF	Citations
109	Diabetic Nephropathy and Proximal Tubular Damage. , 2015, 25, 230-233.		19
110	BMP7 reduces inflammation and oxidative stress in diabetic tubulopathy. Clinical Science, 2015, 128, 269-280.	4.3	34
111	Combined blockade of angiotensin II and prorenin receptors ameliorates podocytic apoptosis induced by IgA-activated mesangial cells. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 907-920.	4.9	13
112	The Treatment of IgA Nephropathy. Kidney Diseases (Basel, Switzerland), 2015, 1, 19-26.	2.5	7
113	Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer's Disease. Current Medicinal Chemistry, 2015, 22, 2392-2403.	2.4	29
114	Mesenchymal Stem Cells Modulate Albumin-Induced Renal Tubular Inflammation and Fibrosis. PLoS ONE, 2014, 9, e90883.	2.5	64
115	Tissue Kallikrein Mediates Pro-Inflammatory Pathways and Activation of Protease-Activated Receptor-4 in Proximal Tubular Epithelial Cells. PLoS ONE, 2014, 9, e88894.	2.5	36
116	Crosstalk between Podocytes and Tubular Epithelial Cells. Contributions To Nephrology, 2014, , 54-63.	1.1	4
117	Albumin and glycated albumin activate KIM-1 release in tubular epithelial cells through distinct kinetics and mechanisms. Inflammation Research, 2014, 63, 831-839.	4.0	3
118	Toll-like receptor activation: from renal inflammation to fibrosis. Kidney International Supplements, 2014, 4, 20-25.	14.2	70
119	Simultaneous determination of berberine and palmatine in human plasma and in urine by capillary electrophoresis combined with polypropylene hollow fiber liquid–liquid–liquid microextraction. Analytical Methods, 2014, 6, 7928-7934.	2.7	14
120	BMPâ€7 represses albuminâ€induced chemokine synthesis in kidney tubular epithelial cells through destabilization of NFâ€î•Bâ€inducing kinase. Immunology and Cell Biology, 2014, 92, 427-435.	2.3	12
121	Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrology Dialysis Transplantation, 2014, 29, 746-754.	0.7	67
122	The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney International, 2013, 83, 887-900.	5.2	106
123	Intestinal absorption and bioavailability of traditional Chinese medicines: a review of recent experimental progress and implication for quality control. Journal of Pharmacy and Pharmacology, 2013, 65, 621-633.	2.4	41
124	Kidney injury moleculeâ€1: More than just an injury marker of tubular epithelial cells?. Journal of Cellular Physiology, 2013, 228, 917-924.	4.1	117
125	Hepatitis C Virus-Associated Glomerulonephritis. Contributions To Nephrology, 2013, 181, 194-206.	1.1	11
126	An ACACB Variant Implicated in Diabetic Nephropathy Associates with Body Mass Index and Gene Expression in Obese Subjects. PLoS ONE, 2013, 8, e56193.	2.5	11

#	Article	IF	Citations
127	Current practices in the management of diabetic nephropathy. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 330-333.	0.6	19
128	A Study of the Clinical and Biochemical Profile of Peritoneal Dialysis Fluid Low in Glucose Degradation Products. Peritoneal Dialysis International, 2012, 32, 280-291.	2.3	37
129	Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrology Dialysis Transplantation, 2012, 27, 613-618.	0.7	35
130	Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 86-102.	6.1	313
131	Quantification of BK Viral Load in Asymptomatic Renal Allograft Recipients. Renal Failure, 2012, 34, 550-554.	2.1	5
132	Impact of nephrotic edema of the lower limbs on obstructive sleep apnea: gathering a unifying concept for the pathogenetic role of nocturnal rostral fluid shift. Nephrology Dialysis Transplantation, 2012, 27, 2788-2794.	0.7	26
133	The role of leptin and its short-form receptor in inflammation in db/db mice infused with peritoneal dialysis fluid. Nephrology Dialysis Transplantation, 2012, 27, 3119-3129.	0.7	11
134	The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrology Dialysis Transplantation, 2012, 27, 3049-3056.	0.7	170
135	Comparative Analysis of Caffeoylquinic Acids and Lignans in Roots and Seeds among Various Burdock (Arctium lappa) Genotypes with High Antioxidant Activity. Journal of Agricultural and Food Chemistry, 2012, 60, 4067-4075.	5.2	75
136	Distinct role of matrix metalloproteinase-3 in kidney injury molecule-1 shedding by kidney proximal tubular epithelial cells. International Journal of Biochemistry and Cell Biology, 2012, 44, 1040-1050.	2.8	39
137	The Renin-Angiotensin System. Contributions To Nephrology, 2011, 170, 135-144.	1.1	22
138	Diabetic Tubulopathy: An Emerging Entity. Contributions To Nephrology, 2011, 170, 124-134.	1.1	100
139	Immunomodulatory Agents against IgA Nephropathy. Advances in Oto-Rhino-Laryngology, 2011, 72, 45-49.	1.6	0
140	GAS IN THE RENAL SHADOW OF A PLAIN ABDOMINAL X-RAY: EMPHYSEMATOUS PYELONEPHRITIS. Nephrology, 2011, 16, 119-120.	1.6	0
141	TRANSPLANT KIDNEY HERNIATION IN AN ELDERLY PATIENT. Nephrology, 2011, 16, 349-350.	1.6	4
142	PYREXIA OF UNKNOWN ORIGIN AND PROTEINURIA: AN ENIGMA SOLVED BY RENAL BIOPSY. Nephrology, 2011, 16, 249-250.	1.6	0
143	Differential effects of advanced glycation endâ€products on renal tubular cell inflammation. Nephrology, 2011, 16, 417-425.	1.6	29
144	Additive renoprotective effects of B2-kinin receptor blocker and PPAR-γ agonist in uninephrectomized db/db mice. Laboratory Investigation, 2011, 91, 1351-1362.	3.7	22

#	Article	IF	CITATIONS
145	Additive effect of PPAR- $\hat{1}^3$ agonist and ARB in treatment of experimental IgA nephropathy. Pediatric Nephrology, 2011, 26, 257-266.	1.7	25
146	Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone. Journal of Translational Medicine, 2011, 9, 169.	4.4	29
147	Clinical Course and Outcomes of Single-Organism <i>Enterococcus</i> Peritonitis in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2011, 31, 522-528.	2.3	26
148	Recent Advances in IgA Nephropathy – The Glomerulopodocytic-Tubular Communication. Advances in Oto-Rhino-Laryngology, 2011, 72, 40-44.	1.6	26
149	TRANSHEPATIC PLACEMENT OF HAEMODIALYSIS CATHETER: A SOLUTION FOR VASCULAR ACCESS EXHAUSTION. Nephrology, 2010, 15, 661-662.	1.6	4
150	Sleep apnea is a novel risk predictor of cardiovascular morbidity and death in patients receiving peritoneal dialysis. Kidney International, 2010, 77, 1031-1038.	5.2	58
151	Colonic Diverticulosis as a Risk Factor for Peritonitis in Chinese Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2010, 30, 187-191.	2.3	32
152	Bradykinin and high glucose promote renal tubular inflammation. Nephrology Dialysis Transplantation, 2010, 25, 698-710.	0.7	58
153	Renoprotection by Rosiglitazone in Accelerated Type 2 Diabetic Nephropathy: Role of STAT1 Inhibition and Nephrin Restoration. American Journal of Nephrology, 2010, 32, 145-155.	3.1	28
154	In vitro enhanced chemotaxis of CD25+ mononuclear cells in patients with familial IgAN through glomerulotubular interactions. American Journal of Physiology - Renal Physiology, 2010, 299, F359-F368.	2.7	8
155	Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney International, 2010, 77, 543-549.	5.2	147
156	The acetyl-coenzyme A carboxylase beta (ACACB) gene is associated with nephropathy in Chinese patients with type 2 diabetes. Nephrology Dialysis Transplantation, 2010, 25, 3931-3934.	0.7	37
157	Diabetic nephropathy: a global and growing threat. Hong Kong Medical Journal, 2010, 16, 244-5.	0.1	20
158	The ubiquitin-proteasome pathway and IgA nephropathy: a novel link?. Kidney International, 2009, 75, 457-459.	5.2	11
159	Macromolecular IgA1 taken from patients with familial IgA Nephropathy or their asymptomatic relatives have higher reactivity to mesangial cells in vitro. Kidney International, 2009, 75, 1330-1339.	5.2	32
160	Improvement in Sleep Apnea during Nocturnal Peritoneal Dialysis Is Associated with Reduced Airway Congestion and Better Uremic Clearance. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 410-418.	4.5	105
161	Crosstalk between peroxisome proliferator-activated receptor- \hat{l}^3 and angiotensin II in renal tubular epithelial cells in IgA nephropathy. Clinical Immunology, 2009, 132, 266-276.	3.2	32
162	Roles of Neutrophil Gelatinase-Associated Lipocalin in Continuous Ambulatory Peritoneal Dialysis-Related Peritonitis. Journal of Clinical Immunology, 2009, 29, 365-378.	3.8	24

#	Article	IF	CITATIONS
163	Other Immunomodulatory Agents. , 2009, , 339-348.		O
164	Complement Activation. , 2009, , 237-241.		0
165	Routine Investigations for Dialysis Patients. , 2009, , 301-305.		0
166	Assessment of Patients with Renal Diseases. , 2009, , 3-13.		0
167	Rhodococcus lung abscess complicating kidney transplantation: successful management by combination antibiotic therapy. Transplant Infectious Disease, 2008, 10, 44-47.	1.7	26
168	Activation of podocytes by mesangial-derived TNF-α: glomerulo-podocytic communication in IgA nephropathy. American Journal of Physiology - Renal Physiology, 2008, 294, F945-F955.	2.7	116
169	Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. Kidney International, 2008, 73, 288-299.	5.2	35
170	BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney International, 2008, 74, 1026-1039.	5.2	23
171	Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrology Dialysis Transplantation, 2008, 24, 62-72.	0.7	135
172	Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis. Nephrology Dialysis Transplantation, 2008, 24, 458-469.	0.7	31
173	Does automated peritoneal dialysis provide better outcomes than continuous ambulatory peritoneal dialysis?. Nature Clinical Practice Nephrology, 2007, 3, 596-597.	2.0	3
174	A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus, 2007, 16, 46-51.	1.6	68
175	Delaying initiation of dialysis till symptomatic uraemiais it too late?. Nephrology Dialysis Transplantation, 2007, 22, 1926-1932.	0.7	51
176	Synthesis of TNF-Â by mesangial cells cultured with polymeric anionic IgA role of MAPK and NF-ÂB. Nephrology Dialysis Transplantation, 2007, 23, 72-81.	0.7	59
177	Interaction between proximal tubular epithelial cells and infiltrating monocytes/T cells in the proteinuric state. Kidney International, 2007, 71, 526-538.	5. 2	49
178	Glycosylation Profile of Differently Charged IgA1 and Their Binding Characteristics to Cultured Mesangial Cells in IgA Nephropathy. Nephron Experimental Nephrology, 2007, 107, e107-e118.	2.2	4
179	Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology, 2007, 12, 576-581.	1.6	64
180	Inability to start hemodialysis after a smooth temporary hemodialysis catheter insertion procedure. Hemodialysis International, 2007, 11 , 32 -4.	0.9	0

#	Article	IF	CITATIONS
181	Tired but can't sleep. Peritoneal Dialysis International, 2007, 27, 647-50.	2.3	2
182	Activation of Tubular Epithelial Cells in Diabetic Nephropathy and the Role of the Peroxisome Proliferator–Activated Receptor-γ Agonist. Journal of the American Society of Nephrology: JASN, 2006, 17, 1633-1643.	6.1	81
183	Alleviation of Sleep Apnea in Patients with Chronic Renal Failure by Nocturnal Cycler–Assisted Peritoneal Dialysis Compared with Conventional Continuous Ambulatory Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2006, 17, 2607-2616.	6.1	131
184	A sleep study with positional hypoxemia. Sleep Medicine, 2006, 7, 383-384.	1.6	0
185	Leptin induces TGF- \hat{l}^2 synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney International, 2006, 69, 2078-2086.	5.2	45
186	Hepatitis B-related membranous nephropathy should be treated with a specific anti-viral agent. Kidney International, 2006, 70, 818.	5.2	6
187	Diagnosis of Patent Processus Vaginalis by Computed Tomography Peritoneography in Continuous Ambulatory Peritoneal Dialysis. Hong Kong Journal of Nephrology, 2006, 8, 78-79.	0.0	0
188	Quiz Page Answers August 2006. American Journal of Kidney Diseases, 2006, 48, e11-e12.	1.9	0
189	Ganoderma extract prevents albumin-induced oxidative damage and chemokines synthesis in cultured human proximal tubular epithelial cells. Nephrology Dialysis Transplantation, 2006, 21, 1188-1197.	0.7	22
190	Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. Nephrology Dialysis Transplantation, 2006, 21, 3243-3251.	0.7	12
191	Chronic viral hepatitis in hemodialysis patients. Hemodialysis International, 2005, 9, 169-179.	0.9	49
192	Minimal and optimal peritoneal Kt/V targets: Results of an anuric peritoneal dialysis patient's survival analysis. Kidney International, 2005, 67, 2032-2038.	5.2	52
193	Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney International, 2005, 68, 802-812.	5.2	149
194	Lamivudine in hepatitis B-associated membranous nephropathy. Kidney International, 2005, 68, 1750-1758.	5.2	113
195	Activation of tubular epithelial cells by mesangial-derived TNF-α: Glomerulotubular communication in IgA nephropathy. Kidney International, 2005, 67, 602-612.	5.2	92
196	Differential expression of aquaporins in the kidneys of streptozotocin-induced diabetic mice. Nephrology, 2005, 10, 63-72.	1.6	13
197	Treatment for lupus nephritis: A revisit. Review Article. Nephrology, 2005, 10, 180-188.	1.6	20
198	Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus, 2005, 14, 947-952.	1.6	54

#	Article	IF	Citations
199	Tubular Expression of Angiotensin II Receptors and Their Regulation in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 2306-2317.	6.1	70
200	Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. Nephrology Dialysis Transplantation, 2005, 20, 1336-1349.	0.7	55
201	Glomerular Pathology of Allograft Kidneys in Hong Kong. Transplantation Proceedings, 2005, 37, 4293-4296.	0.6	7
202	Spousal renal donor transplantation in Chinese subjects: a 10 year experience from a single centre. Nephrology Dialysis Transplantation, 2004, 19, 203-206.	0.7	21
203	Anti-macrophage migration inhibitory factor reduces transforming growth factor-Â1 expression in experimental IgA nephropathy. Nephrology Dialysis Transplantation, 2004, 19, 1976-1985.	0.7	44
204	Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clinical and Experimental Immunology, 2004, 138, 466-475.	2.6	39
205	Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney International, 2004, 66, 1403-1416.	5.2	44
206	Physiologic Inhibitors of Coagulation in Patients on Chronic Hemodialysis. Hemodialysis International, 2003, 7, 232-238.	0.9	0
207	Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. Journal of Hepatology, 2003, 39, 875-878.	3.7	58
208	Polymeric IgA1 from Patients with IgA Nephropathy Upregulates Transforming Growth Factor- \hat{l}^2 Synthesis and Signal Transduction in Human Mesangial Cells via the Renin-Angiotensin System. Journal of the American Society of Nephrology: JASN, 2003, 14, 3127-3137.	6.1	80
209	Video-assisted thoracoscopic talc pleurodesis is effective for maintenance of peritoneal dialysis in acute hydrothorax complicating peritoneal dialysis. Nephrology Dialysis Transplantation, 2003, 18, 804-808.	0.7	81
210	Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 36-45.	0.7	48
211	Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. Journal of Clinical Investigation, 2003, 111, 515-527.	8.2	234
212	Role of Complement in Tubulointerstitial Injury from Proteinuria. Kidney and Blood Pressure Research, 2002, 25, 120-126.	2.0	28
213	Characteristics of Polymeric î»-lgA Binding to Leukocytes in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, 2309-2319.	6.1	15
214	Post-transplantation Lymphoproliferative Disease in Chinese: The Queen Mary Hospital Experience in Hong Kong. Leukemia and Lymphoma, 2002, 43, 1403-1407.	1.3	18
215	Free-hand, ultrasound-guided percutaneous renal biopsy: experience from a single operator. European Journal of Radiology, 2002, 41, 65-69.	2.6	42
216	Size-dependent binding of IgA to HepG2, U937, and human mesangial cells. Translational Research, 2002, 140, 398-406.	2.3	27

#	Article	IF	CITATION
217	Real-time quantitative analysis of polyoma BK viremia and viruria in renal allograft recipients. Journal of Virological Methods, 2002, 103, 51-56.	2.1	78
218	Increased sialylation of polymeric λ″gA ₁ in patients with IgA nephropathy. Journal of Clinical Laboratory Analysis, 2002, 16, 11-19.	2.1	38
219	Transferrin up-regulates chemokine synthesis by human proximal tubular epithelial cells: Implication on mechanism of tubuloglomerular communication in glomerulopathic proteinura. Kidney International, 2002, 61, 1655-1665.	5.2	45
220	Transferrin but not albumin mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. American Journal of Kidney Diseases, 2001, 37, 94-103.	1.9	45
221	Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy. Kidney International, 2001, 59, 277-285.	5.2	53
222	INCREASED SURVIVAL OF MESOTHELIAL CELLS FROM THE PERITONEUM IN PERITONEAL DIALYSIS FLUID. Cell Biology International, 2001, 25, 445-450.	3.0	7
223	Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 2001, 38, 1055-1060.	1.9	64
224	Risk factors for avascular bone necrosis after renal transplantation. Transplantation Proceedings, 2000, 32, 1873-1875.	0.6	48
225	Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus, 1999, 8, 545-551.	1.6	66
226	Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 1998, 32, 1011-1018.	1.9	53
227	Resolution of eosinophilic peritonitis with Ketotifen. American Journal of Kidney Diseases, 1997, 30, 433-436.	1.9	29